PolyPeptide Group AG (PPGN.SW)
Swiss · CHF · Healthcare · Drug Manufacturers - Specialty & Generic
CHF 43.60 (-0.46%) as of
Key statistics
- Market cap
- 1.44B
- P/E (TTM)
- 106.34
- Forward P/E
- 31.13
- EPS (TTM)
- 0.41
- Dividend yield
- 0.00%
- 52-week range
- 21.80 – 50.10
- Beta
- 0.97
- Revenue (TTM)
- 458.86M
- Profit margin
- 3.15%
- Analyst target
- CHF 42.47
- Volume
- 1.73k
About PolyPeptide Group AG
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, pharmaceutical, and biotech companies. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Baar, Switzerland
- Employees
- 1,460
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.